The Unsustainable Cost of Clinical Development in 2026

Clinical development has always been expensive. But in 2026, the economics are drawing sharper attention. Developing a single new molecular entity now routinely requires between $2 billion and $2.6 billion per approved drug, when accounting for capital costs and the rate of clinical failures across a development lifecycle that can span 10 to 15 years.